glp-1 discontinuation Members of $MED's Scientific and Clinical Affairs team and Medifast's Scientific Advisory Board recently published an article in Diabetes, Obesity and Metabolism, highlighting rates. While GLP-1s* represent a significant advancement A Comprehensive Review on Weight

CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition

What the research actually says which is: not much, yet

The Lancet 2026 For deeper curations and analysis on digital health, AI, and evidence-based decision-making, I share regular insights in my newsletter Evidence Decoded.Join here: This is becoming one of the most well-evidenced drug classes in modern medicine

Este medicamento se administra principalmente por va intravenosa y suele proporcionarse en un entorno hospitalario o mdico

The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis

Stopping at 2 weeks means ending the protocol during the early repair phase